Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1088-1096

  Bezard, Erwan ^a,b,c   Tronci, Elisabetta ^d,e   Pioli, Elsa Y ^f   Li, Qin ^c,f   Porras, Gregory ^f   Björklund, Anders ^e   Carta, Manolo ^d,e  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CNRS   (France)

^c INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e LUND UNIVERSITY   (Sweden)

^f Williams House   (United Kingdom)

Author keywords

Amantadine; Dyskinesia; Eltoprazine; Levodopa; Serotonin

Indexed keywords

AMANTADINE; ELTOPRAZINE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DYSKINESIA; FEMALE; LOW DRUG DOSE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; THERAPY EFFECT;

AMANTADINE; DYSKINESIA; ELTOPRAZINE; LEVODOPA; SEROTONIN;

AMANTADINE; AMPHETAMINE; ANIMALS; APOMORPHINE; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PIPERAZINES; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN RECEPTOR AGONISTS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84881556666     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25366     Document Type: Article

References (24)

1. Sawada H, Oeda T, Kuno S, et al. Amantadine Study Group. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial [serial online]. PLoS One 2010;31;5(12):e15298.
2. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10:377-393.
3. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-1833.
4. Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008;131:3380-3394.
5. Navailles S, Bioulac B, Gross C, De Deurwaerdere P. Chronic l-dopa therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis 2011;41:585-590.
6. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82.
7. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22:179-186.
8. Miczek KA, Mos J, Olivier B. Brain 5-HT and inhibition of aggressive behavior in animals: 5-HIAA and receptor subtypes. Psychopharmacol Bull 1989;25:399-403.
9. Mos J, Olivier B, Poth M, van Aken H. The effects of intraventricular administration of eltoprazine, 1-(3-trifluoromethylphenyl)piperazine hydrochloride and 8-hydroxy-2-(di-n-propylamino)tetralin on resident intruder aggression in the rat. Eur J Pharmacol 1992; 212:295-298.
10. Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA. Sarizotan, a serotonin 5-HT1a receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 2004;111:113-126.
11. Peroutka SJ. Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry 1985;20:971-979.
12. Olivier B, Mos JM, Tulp M, Schipper J, Bevan P. Modulatory action of serotonin in aggressive behavior. In: Bevan P, Cools AR, Archer T, eds. Behavioral Pharmacology of 5-HT. Hillsdale, NJ: Lawrence Erlbaum Associates; 1989:89-115.
13. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002;15:120-132.
14. Munoz A, Carlsson T, Tronci E, Kirik D, Bjorklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009;219:298-307.
15. Schallert T, Tillerson J. Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimising behavioral assessment of outcome. In: Emerich DF, Dean RL III, Sandberg PR, eds. Innovative Models of CNS Disease: From Molecule to Therapy. Clifton, NJ: Human Press; 1999:131-151.
16. Kirik D, Winkler C, Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci 2001;21:2889-2896.
17. Ahmed MR, Berthet A, Bychkov E, et al. Lentiviral overexpression of GRK6 alleviates l-dopa-induced dyskinesia in experimental Parkinson's disease [serial online]. Sci Transl Med 2010;2:28ra28.
18. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853-6861.
19. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.
20. Fasano A, Daniele A, Albanese A. Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: need for long-term clinical trials [letter]. Mov Disord 2011;26:1370; author reply 1371.
21. Guigoni C, Dovero S, Aubert I, et al. Levodopa-induced dyskinesia in MPTP-treated macaque is not dependent of the extent and pattern of the nigrostrial lesion. Eur J Neurosci 2005;22:283-287.
22. Gold SJ, Hoang CV, Potts BW, et al. RGS9-2 negatively modulates L-3, 4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci 2007;27:14338-14348.
23. Porras G, Berthet A, Dehay B, et al. PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 2012;22:3977-3989
24. Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. A critique of available scales and presentation of the non-human primate dyskinesia rating scale. Mov Disord 2012;27:1373-1378.